Research news

Facio Therapies has announced that it has selected several compounds as lead candidates for its FSHD drug development programme.

Genea Biocells has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to GBC0905 for the treatment of FSHD.

Acceleron Pharma has announced the US Food and Drug Administration has granted Fast Track Designation to ACE-083.

Acceleron Pharma has announced the US Food and Drug Administration has granted Fast Track Designation to ACE-083, for the treatment of FSHD.

Acceleron Pharmaceuticals has announced preliminary results from its phase 2 trial testing ACE-083 in adults with facioscapulohumeral muscular dystrophy (FSHD).

A research study using data from the UK Facioscapulohumeral muscular dystrophy (FSHD) Patient Registry has been published recently.

Acceleron Pharma has released an update on its neuromuscular programme. It is currently developing two drugs that aim to increase muscle mass by blocking myostatin.

It was not known whether facioscapulohumeral muscular dystrophy (FSHD) affects bone health, and a recent study published in Muscle & Nerve begins to address this question.

We would like to inform you of a research study for adults with progressive muscle weakness caused by muscular dystrophy or inclusion body myositis (IBM).

Facio Therapies announced today that it has raised €4.8 million from a group of shareholders.